The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 07, 2023

Filed:

Aug. 11, 2017
Applicant:

Boehringer Ingelheim International Gmbh, Ingelheim am Rhein, DE;

Inventors:

Patrick Garidel, Biberach an der Riss, DE;

Sven Bahrenburg, Biberach an der Riss, DE;

Torsten Schultz-Fademrecht, Aepfingen, DE;

Andrea Eiperle, Grodt, DE;

Assignee:

Boehringer Ingelheim International GmbH, Ingelheim an Rhein, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 1/34 (2006.01); A61K 9/08 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01);
U.S. Cl.
CPC ...
C07K 1/34 (2013.01); A61K 9/08 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01);
Abstract

It is disclosed an improved multi-step process for the preparation of a highly concentrated liquid formulation containing biomolecules comprising the steps of (a) a first ultrafiltration UF1; (b) a first diafiltration DF1; (c) a second diafiltration DF2; and (d) a second ultrafiltration UF2; wherein an aqueous solution of one or more salts, as liquid medium B, is used for step (b) and water or an aqueous solution of one or more salts, as liquid medium C, is used for step (c), wherein the one or more salts used for step (b) are the same or different from the one or more salts used for step (c) and wherein the liquid medium B has an ionic strength which is higher than the ionic strength of the liquid medium C. The process according to the present invention allows the preparation of well-defined highly concentrated formulations containing biomolecules, particularly proteins, intended for pharmaceutical or non-pharmaceutical use. Unwanted excipient(s) of the starting liquid biomolecule formulation, may be reduced under solution conditions, to very low levels or levels lower than the detection limit.


Find Patent Forward Citations

Loading…